CBS 2019
CBSMD教育中心
中 文

推荐文献

Abstract

Recommended Article

Classification of Deaths in Cardiovascular Outcomes Trials Known Unknowns and Unknown Unknowns Catheterization Laboratory Considerations During the Coronavirus (COVID-19) Pandemic: From the ACC’s Interventional Council and SCAI In-Hospital Costs and Costs of Complications of Chronic Total Occlusion Angioplasty Insights From the OPEN-CTO Registry Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials Genetics and Causality of Triglyceride-Rich Lipoproteins in Atherosclerotic Cardiovascular Disease Disrupting Fellow Education Through Group Texting: WhatsApp in Fellow Education? Healthy Behavior, Risk Factor Control, and Survival in the COURAGE Trial Can the Vanishing Stent Reappear? Fix the Technique, or Fix the Device?

Review Article2017 Jun 6;69(22):2759-2768.

JOURNAL:J Am Coll Cardiol. Article Link

LOX-1 in Atherosclerosis and Myocardial Ischemia: Biology, Genetics, and Modulation

Pothineni NVK, Karathanasis SK, Mehta JL et al. Keywords: LOX-1 blockers; coronary artery disease; endothelial cells; low-density lipoprotein; myocardial infarction; reactive oxygen species

ABSTRACT


Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1), one of the scavenger receptors for oxidized low-density lipoprotein cholesterol (ox-LDL), plays a crucial role in the uptake of ox-LDL by cells in the arterial wall. Mounting evidence suggests a role for LOX-1 in various steps of the atherosclerotic process, from initiation to plaque destabilization. Studies of the genetic structure of LOX-1 have also uncovered various genetic polymorphisms that could modulate the risk of atherosclerotic cardiovascular events. As evidence supporting the vital role of LOX-1 in atherogenesis keeps accumulating, there is growing interest in LOX-1 as a potential therapeutic target. This review discusses the discovery and genetics of LOX-1; describes existing evidence supporting the role of LOX-1 in atherogenesis and its major complication, myocardial ischemia; and summarizes LOX-1 modulation by some naturally occurring compounds and efforts toward development of small molecules and biologics that could be of therapeutic use.